Simultaneous development of zanubrutinib in the USA and China.

Li, Guanqiao; Liu, Xiaozhen; Chen, Xiaoyuan

Li, Guanqiao; Liu, Xiaozhen; Chen, Xiaoyuan.

Li G; Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing, China.
Liu X; Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing, China.
Chen X; Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing, China. cxya02648@mail.tsinghua.edu.cn.

Nat Rev Clin Oncol ; 17(10): 589-590, 2020 10.

Article in English | MEDLINE | ID: covidwho-1033856

Subject(s)

Drug Approval/legislation & jurisprudence; Drug Development/organization & administration; Lymphoma, Mantle-Cell/drug therapy; Piperidines/therapeutic use; Protein Kinase Inhibitors/therapeutic use; Pyrazoles/therapeutic use; Pyrimidines/therapeutic use; China; Clinical Trials as Topic; Health Care Reform/legislation & jurisprudence; Humans; Treatment Outcome; United States; United States Food and Drug Administration

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Piperidines / Pyrazoles / Pyrimidines / Drug Approval / Lymphoma, Mantle-Cell / Protein Kinase Inhibitors / Drug Development Type of study: Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America / Asia Language: English Journal: Nat Rev Clin Oncol Journal subject: Neoplasms Year: 2020 Document Type: Article Affiliation country: S41571-020-0414-y

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google